Ignite Creation Date:
2024-05-06 @ 4:01 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04849273
Status:
TERMINATED
Last Update Posted:
2023-05-26
First Post:
2021-04-12
Brief Title:
A Study of TPX-0131 a Novel Oral ALK Tyrosine Kinase Inhibitor in Patients With ALK Advanced or Metastatic NSCLC
Sponsor:
Turning Point Therapeutics Inc
Organization:
Turning Point Therapeutics Inc
Organization Data
Organization:
Turning Point Therapeutics Inc
Class:
INDUSTRY
Study ID:
CA226-1036
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Turning Point Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None